Cretostimogene reduced recurrence risk in intermediate-risk and high-grade Ta non-muscle invasive bladder cancer in topline phase 3 results
Topline PIVOT-006 results found that cretostimogene reduced recurrence risk versus surveillance in intermediate-risk and high-grade Ta non-muscle invasive bladder cancer.


